RT Journal Article SR Electronic T1 The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 JF Journal for ImmunoTherapy of Cancer JO J Immunother Cancer FD BMJ Publishing Group Ltd SP e000921 DO 10.1136/jitc-2020-000921 VO 8 IS 2 A1 Paolo A Ascierto A1 Carlo Bifulco A1 Jerome Galon A1 Claus Garbe A1 Samir N Khleif A1 Jennifer McQuade A1 Kunle Odunsi A1 Hideho Okada A1 Chrystal M Paulos A1 Sergio A Quezada A1 Hussein A Tawbi A1 John Timmerman A1 Giorgio Trinchieri A1 Lisa H Butterfield A1 Igor Puzanov YR 2020 UL http://jitc.bmj.com/content/8/2/e000921.abstract AB As part of the 2019 Immunotherapy Bridge congress (December 4–5, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on six topical issues in immunotherapy today. These were the use of chimeric antigen receptor T cell therapy in solid tumors, whether the Immunoscore should be more widely used in clinical practice, whether antibody-dependent cellular cytotoxicity is important in the mode of action of anticytotoxic T-lymphocyte-associated protein 4 antibodies, whether the brain is immunologically unique or just another organ, the role of microbiome versus nutrition in affecting responses to immunotherapy, and whether chemotherapy is immunostimulatory or immunosuppressive. Discussion of these important topics are summarized in this report.